DAE HWA Pharmaceutical Co. Ltd
DAE HWA Pharmaceutical Co., Ltd., a pharmaceutical company, produces and supplies pharmaceutical products in South Korea. The company offers drugs for anticancer, antibiotics, antifungal and skin ailment, antivirus, anti-allergosis, hemorrhoids, antidepressant, antiepileptic, psychotropic agent, anti respiratory, anti-inflammatory, analgesic, skeletal muscle relaxants, osteoporosis, anti-arthriti… Read more
DAE HWA Pharmaceutical Co. Ltd (067080) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.014x
Based on the latest financial reports, DAE HWA Pharmaceutical Co. Ltd (067080) has a cash flow conversion efficiency ratio of -0.014x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-1.00 Billion) by net assets (₩73.73 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
DAE HWA Pharmaceutical Co. Ltd - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how DAE HWA Pharmaceutical Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
DAE HWA Pharmaceutical Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DAE HWA Pharmaceutical Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Meliá Hotels International S.A
PINK:SMIZF
|
0.178x |
|
Stellar V Capital Corp. Class A Ordinary Shares
NASDAQ:SVCC
|
0.000x |
|
Cipher Pharmaceuticals Inc
OTCQX:CPHRF
|
0.094x |
|
Zueblin Immobilien Holding AG
SW:ZUBN
|
0.019x |
|
Kec Corporation
KO:092220
|
-0.006x |
|
LIVECHAT SOFTW.AB ZY-02
F:886
|
N/A |
|
Sterling Bancorp Inc
NASDAQ:SBT
|
-0.012x |
|
ZALARIS ASA A NK -10
F:81Y
|
N/A |
Annual Cash Flow Conversion Efficiency for DAE HWA Pharmaceutical Co. Ltd (2011–2024)
The table below shows the annual cash flow conversion efficiency of DAE HWA Pharmaceutical Co. Ltd from 2011 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩72.00 Billion | ₩6.13 Billion | 0.085x | +1155.66% |
| 2023-12-31 | ₩73.23 Billion | ₩-590.27 Million | -0.008x | -107.81% |
| 2022-12-31 | ₩77.99 Billion | ₩8.05 Billion | 0.103x | -21.32% |
| 2021-12-31 | ₩79.67 Billion | ₩10.45 Billion | 0.131x | +270.58% |
| 2020-12-31 | ₩81.98 Billion | ₩2.90 Billion | 0.035x | +6935.37% |
| 2019-12-31 | ₩79.35 Billion | ₩-41.07 Million | -0.001x | -100.38% |
| 2018-12-31 | ₩76.88 Billion | ₩10.49 Billion | 0.136x | -4.30% |
| 2017-12-31 | ₩76.75 Billion | ₩10.94 Billion | 0.143x | +7.31% |
| 2016-12-31 | ₩66.15 Billion | ₩8.79 Billion | 0.133x | +233.71% |
| 2015-12-31 | ₩61.06 Billion | ₩2.43 Billion | 0.040x | -62.31% |
| 2014-12-31 | ₩58.51 Billion | ₩6.18 Billion | 0.106x | -51.73% |
| 2013-12-31 | ₩62.03 Billion | ₩13.57 Billion | 0.219x | +132.79% |
| 2012-12-31 | ₩61.39 Billion | ₩5.77 Billion | 0.094x | +56.14% |
| 2011-12-31 | ₩56.99 Billion | ₩3.43 Billion | 0.060x | -- |